癌症疼痛患者美沙酮QTc间期延长的风险:回顾性队列研究
该研究回顾性分析492例接受美沙酮治疗癌症疼痛的成人患者,发现美沙酮起始≥12个月后QTc间期平均增加4.36 ms,合并心脏疾病者增加9.40 ms;QTc延长比例从基线3%升至12个月后6.8%。结论认为美沙酮相关QTc延长风险较低,建议风险分层心电图监测。
要点
- 美沙酮起始≥12个月后QTc平均增加4.36毫秒,幅度较小。
- 合并心脏疾病者QTc增加9.40毫秒,需重点关注。
- QTc延长比例从3%升至6.8%,总体风险低,建议风险分层监测。
核心结论
- 在肿瘤患者中,美沙酮用于癌痛管理与小但统计学显著的QTc间期延长相关,且主要出现在起始≥12个月后。
- 该幅度QTc变化对多数患者不太可能产生有临床意义的表现,支持大多数患者QTc延长风险较低。
研究设计与样本
- 回顾性病历审查,纳入492例接受美沙酮治疗癌症相关疼痛的成人患者。
- 收集人口学与临床数据,并在基线及起始后0-6、6-12、≥12个月提取QTc间期。
主要发现
- 线性混合效应模型显示美沙酮起始≥12个月后QTc间期增加4.36 ms,具统计学显著性。
- 合并心脏疾病与QTc增加9.40 ms相关,具统计学显著性。
- 其他时间段、人口学或临床特征与QTc变化无统计学显著关联。
- QTc延长总体比例从基线3%升至起始后12个月6.8%。
关键数值与推荐
- 美沙酮起始≥12个月后QTc间期平均增加约4 ms(4.36 ms)。
- 合并心脏疾病者QTc间期平均增加9.40 ms。
- QTc延长比例从基线3%升至12个月后6.8%。
临床怎么用
- 对大多数癌症疼痛患者,美沙酮QTc延长风险较低,可支持临床使用。
- 建议采用风险分层方法,对基线QTc升高或合并心脏疾病者进行针对性心电图监测。
局限性
- 原文摘要未明确报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Methadone is commonly used as an alternative to other opioids for managing cancer-related pain. High-dose methadone, primarily in opioid dependence treatment, has been associated with QTc prolongation and dangerous arrhythmias. The cardiovascular effects of methadone at lower doses, as used in cancer pain management, remain less well characterized. METHODS: We conducted a retrospective chart review of 492 adult patients who received methadone for cancer-related pain management. For each patient, we collected demographic and clinical data, including age, sex, cancer diagnosis, initial methadone dosage, adjuvant medications, and comorbidities. QTc interval measurements were extracted from ECGs performed at baseline (within 12 months prior to methadone initiation) and at follow-up intervals of 0-6 months, 6-12 months, and ≥12 months after initiation. RESULTS: The linear mixed-effects model shows a statistically significant increase in QTc interval by 4.36 ms at ≥12 months after methadone initiation. The prevalence of cardiac comorbidities was associated with a statistically significant increase in QTc by 9.40 ms. No other timeframe, demographic characteristic, or clinical characteristic that we investigated was associated with a statistically significant change in QTc. The overall proportion of patients with QTc prolongation increased modestly from 3% at baseline to 6.8% after 12 months following the initiation of methadone. CONCLUSION: In this large retrospective cohort of oncology patients receiving methadone for pain management, methadone was associated with a small but statistically significant increase in QTc interval ≥12 months after starting therapy, with a mean increase of approximately 4 ms. This magnitude of QTc change is unlikely to produce meaningful clinical manifestations for most patients. These findings support the low risk of QTc prolongation for most patients with cancer taking methadone and encourage a risk-stratified approach to methadone use in cancer pain with targeted ECG monitoring regimens for patients with elevated baseline QTc or underlying cardiac disease.
引用
- Li DY, Kim S, Javed S, et al. Evaluating the risk of methadone and QTc interval prolongation in an oncologic population. Reg Anesth Pain Med. 2026. PMID: 41702654. doi:10.1136/rapm-2025-107328
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。